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INTRODUCTION
The incidence of distant metastases in non-small cell lung
cancer (NSCLC) is reported in 40% or more of patients with
the disease at the time of diagnosis (1, 2). In spite of the high
percentage of extra-thoracic metastases, there has been no
consensus recommendation for extra-thoracic metastasis eval-
uation using various imaging modalities. International med-
ical associations have different opinions about the use of imag-
ing (3, 4). One society suggests full scanning for metastatic
disease, even if patients lack symptoms and signs of metastat-
ic disease (3). Another society advocates no preoperative imag-
ing of the brain or skeleton in NSCLC patients without symp-
toms or signs of a distant metastasis (4).
The use of integrated fluorine 18fluorodeoxyglucose (FDG)
positron emission tomography (PET)/computed tomogra-
phy (CT) is more efficient to assess the presence of a metas-
tasis of both the mediastinal and extra-thoracic regions than
the use of standard methods (5, 6). However, FDG PET or
PET/CT has some limitation for brain metastasis evaluation,
because it is difficult to differentiate FDG-avid metastases
from the normal surrounding hyper-metabolic parenchyma
in brain (7). Metastatic lesion to the brain may present in up
to 18% of patients with NSCLC (8, 9). Particularly in ade-
nocarcinoma of the lung, the brain metastasis rate has been
reported to be 43% (58 of 136 patients) in one study (10).
Considering the high percentage of the brain metastasis rate
in lung adenocarcinoma patients and the limited efficacy of
PET or PET/CT for detecting brain metastasis, PET or PET/
CT plus an additional brain imaging modality (magnetic
resonance imaging [MRI] or CT) may be needed for staging
of lung adenocarcinoma. The purpose of our study was to
evaluate prospectively the efficacy of PET/CT plus 3T brain
MRI for detecting extrathoracic metastases in lung adeno-
carcinoma.
MATERIALS AND METHODS
The Institutional Review Board approved this prospective
study and informed consent was obtained from all patients
(2008-07-019).
Patients
From November 2003 to December 2006, 520 consecu-
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Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of
Extrathoracic Metastases in Patients with Lung Adenocarcinoma
We aimed to evaluate prospectively the efficacy of positron emission tomography
(PET)/computed tomography (CT) plus brain magnetic resonance imaging (MRI)
for detecting extrathoracic metastases in lung adenocarcinoma. Metastatic evalua-
tions were feasible for 442 consecutive patients (M:F=238:204; mean age, 54 yr)
with a lung adenocarcinoma who underwent PET/CT (CT, without IV contrast medi-
um injection) plus contrast-enhanced brain MRI. The presence of metastases in
the brain was evaluated by assessing brain MRI or PET/CT, and in other organs
by PET/CT. Diagnostic efficacies for metastasis detection with PET/CT plus brain
MRI and with PET/CT only were calculated on a per-patient basis and compared
from each other. Of 442 patients, 88 (20%, including 50 [11.3%] with brain metas-
tasis) had metastasis. Regarding sensitivity of overall extrathoracic metastasis detec-
tion, a significant difference was found between PET/CT and PET/CT plus brain
MRI (68% vs. 84%; P=0.03). As for brain metastasis detection sensitivity, brain MRI
was significantly higher than PET/CT (88% vs. 24%; P<0.001). By adding MRI to
PET/CT, brain metastases were detected in additional 32 (7% of 442 patients) pati-
ents. In lung adenocarcinoma patients, significant increase in sensitivity can be
achieved for detecting extrathoracic metastases by adding dedicated brain MRI to
PET/CT and thus enhancing brain metastasis detection.
Key Words : PET/CT Scan; Lung Neoplasms; Neoplasm Metastasis; Brain; Magnetic Resonance Imaging;
Neoplasm Staging
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tive patients with histopathologically (cytology or biopsy)
proven adenocarcinoma of the lung (except for bronchioloalve-
olar cell carcinoma which mediastinal nodal or extra-thoracic
metastasis is unusual) were enrolled. All patients were referred
for cancer staging of lung adenocarcinoma. Of these 520 pa-
tients, 78 patients were excluded for the following reasons:
58 patients were unable to undergo brain MRI for the ini-
tial staging, and 20 patients were lost to follow-up. Ultimate-
ly, 442 patients (M:F=238:204; mean age, 54 yr) were includ-
ed in this study, in whom both FDG PET/CT and dedicated
brain MRI were performed for the initial staging and meta-
static evaluations of M staging were feasible with pathologi-
cal results or follow-up imaging studies.
Imaging and interpretation
The presence of metastases in the brain was evaluated by
using brain MRI (Achieva, Philips Medical Systems, Best,
The Netherlands) and PET/CT (Discovery LS; GE Medical
Systems, Milwaukee, WI, U.S.A.), and the presence of metas-
tases in other organs was determined by the use of PET/CT.
PET/CT and MRI were performed within a one-week time
interval (average time interval, 3.1 days; range, 0-7 days).
Detailed imaging methods of integrated PET/CT have been
described in previous reports (5, 11). Briefly, glucose level
in peripheral blood was ≤150 mg/dL in all patients. The
patients received an intravenous injection of 370 MBq (10
mCi) of FDG and then rested for over 45 min before scan-
ning. PET/CT device consisted of a PET scanner (Advance
NXi; GE Healthcare) and an eight-slice CT scanner (Light-
Speed Plus; GE Healthcare). Immediately after taking nonen-
hanced CT, emission PET was performed in the identical
transverse field of view. Co-registered images were displayed
by Xeleris software (GE Healthcare). It took approximately
40 min to complete a PET/CT study. All brain MRI studies
were performed by using a 3-Tesla scanner with a standard
head coil. Brain MR images were obtained in the axial, sagit-
tal, and coronal planes by using three sequences including a
T2-weighted axial turbo spin-echo pulse sequence (repetition
time 3,000 ms, echo time 80 ms) with fat suppression, a fluid-
attenuation inversion-recovery (FLAIR) spin-echo sequence
(repetition time 11,000 ms, echo time 125 ms, inversion time
2,800 ms) and a non-contrast enhanced and a contrast-en-
hanced T1-weighted spin-echo sequence (repetition time
500 ms, echo time 10 ms). The contrast-enhanced sequence
was obtained after bolus injection of a dose of 0.2 mM/kg
paramagnetic contrast agent (Magnevist, Schering, Berlin,
Germany). 
A chest radiologist with 18 yr of experience in CT inter-
pretation and a nuclear medicine physician with four years of
PET/CT interpretation jointly evaluated the integrated PET/
CT images. Both clinicians were unaware of the brain MRI
findings or the clinical and pathological evaluation results.
An abnormal focal FDG uptake that accompanied a corre-
sponding anatomic alteration was considered as the indica-
ton of a metastasis (5, 11). The maximum standardized up-
take value (SUVmax) of the focal metastatic lesion was mea-
sured. All lymph nodes with abnormal FDG uptake (greater
than mediastinal blood pool uptake) in the extrathoracic
regions were considered as metastatic, unless they showed
high attenuation over 70 HU or benign calcification (cen-
tral nodular, laminated, popcorn-like and diffuse) at unen-
hanced CT (12). Two chest radiologists with three years of
experience in whole-body MRI analysis, who were unaware
of the clinical, PET/CT findings or histologic diagnoses, inter-
preted the brain MR images and decisions on findings were
made by consensus. When the two chest radiologists had
different opinions on the presence of brain metastasis, they
sought for the third opinion from neuro-imaging radiologists
and by a majority the presence or absence of brain metasta-
sis was determined.
The probability of the presence of metastases on a per-patient
basis was then evaluated by the use of a five-point visual scor-
ing system: 0, definitely absent; 1, probably absent; 2, pos-
sibly present; 3, probably present; 4, definitely present. Before
interpreting the images, the reviewers were informed that
the categorization of confidence levels of 2 or higher belonged
to a category of positive diagnosis for a metastasis. The largest
diameter of the detected metastatic nodules on brain MR
images and CT component images of PET/CT was measured
and recorded.
Reference standard for metastases 
The final decisions on the presence of extra-thoracic metas-
tases in each patient were reached based on the results of ded-
icated standard imaging, a pathologic examination, or a fol-
low-up examination. 
Metastatic lesions were confirmed at 121 organ sites from
88 (20%) of the 442 patients. Sixteen lesions of metastases
were pathologically proven. Ninety-four metastatic lesions
were confirmed at the time of initial staging by using the use
of specific organ-dedicated imaging studies, i.e., dedicated
MRI at the time of staging for 58 lesions, dedicated CT for
21 lesions, and bone scan for 15 lesions. The remaining 11
lesions were detected by follow-up dedicated imaging studies
in six months or more, and the lesions were regarded as meta-
static (growth from a microscopic metastatic focus) because
most of the primary cancers in these patients were resected
surgically after the initial staging work-up. 
The absence of a metastasis at 18 sites (from 18 patients)
which were suspected as metastatic at the initial clinical-imag-
ing studies was proven by following methods: negative biopsy
results for metastasis (n=5); surgical excision (n=1) of a sus-
pected adrenal lesion; organ-specific multiphase CT (n=2)
for adrenal lesions; negative bone scan results (n=2); and nega-
tive results for brain metastasis (n=2) by the use of dedicat-
ed conventional MRI and three times of cerebrospinal fluid1134 H.Y. Lee, K.S. Lee, B.-T. Kim, et al.
tapping. In the remaining six patients, the findings of clini-
co-laboratory follow-up studies served as reference standards
for determining the absence of a metastasis. The mean clini-
cal follow-up time for these six patients was 36 months (range,
30-41 months). 
Statistical analysis
The diagnostic efficacy of PET/CT plus brain MRI was cal-
culated on a per-patient basis. Receiver operating character-
istic (ROC) curve analysis was used to compare diagnostic
capabilities and it was compared by using a Z test, as describ-
ed by Hanley and McNeil (12). Sensitivity, specificity, and
accuracy of the two methods were statistically compared by
use of the McNemar’s test. Statistical differences in the size
of PET-detected and PET-missed metastatic lesions were com-
pared by use of the Mann-Whitney U test. A P value <0.05
was considered as a significant difference. 
RESULTS
Patient demographics
Details of the patient characteristics are summarized in
Table 1. Extrathoracic metastatic lesions were confirmed at
121 organ sites for 88 (20%) of the 442 patients. Of the 50
patients with a brain metastasis, 30 (60%) had one organ
(brain) metastasis and 35 (70%) patients had a single lesion
metastasis. Sixteen (53%) of 30 patients with single organ
metastasis to brain had early stage of cancer (stage I or II ex-
cluding brain evaluation) (Table 2). Seven (14%) patients had
neurologic symptoms or signs (headache, dizziness, vomiting
or a neurological deficit) at the time of initial presentation. 
Efficacy of MRI and PET/CT for metastasis detection
The diagnostic efficacies of the two modalities are sum-
Parameters Numbers
Age (yr)
Mean 54
Range 23-88
Sex (cases)
Male 238
Female 204
Stage (cases)
I9 4
II 67
III 157
IV 124
Site-specific metastases (sites)
Brain 50  (11%)
Bone 35 (8%)
Extrathoracic lymph nodes 14 (3%)
Adrenal 10  (2%)
Liver 5 (1%)
Soft tissue 5 (1%)
Kidney 1 (0.2%)
Bowel 1  (0.2%)
Table 1. Characteristics of subjected patients 
TN stage
Clinical stage
excluding brain evaluation
n (%)
T1N0 IA 4 (13)
T2N0 IB 8 (27)
T1N1 IIA 2 (7)
T2N1 IIB 2 (7)
T1N2 IIIA 2 (7)
T2N2 IIIA 2 (7)
T3N1 IIIA 1 (3)
T3N2 IIIA 2 (7)
T4 or N3 IIIB 7 (23)
Total 30
Table 2. Tumor and nodal stage in patients with single organ
metastasis to brain
Variables Brain MRI PET/CT P values
Az value <0.001*
Value 0.935 0.619
95% CI 0.881, 0.989 0.525, 0.713
Sensitivity (%)
�
No neurologic  86 (37/43) 19 (8/43) <0.001
�
sign or symptom
Total 88 (44/50) 24 (12/50) <0.001
�
Specificity (%)
� 98 (385/392) 100 (391/392) 0.26
�
Accuracy (%)
� 97 (429/442) 91 (403/442) 0.12
�
Table 3. ROC analysis and comparison of capability of detec-
tion of brain metastases on a per-patient basis
*P values were calculated by using the Z test; 
� Data in parentheses are
the values used to calculate percentages; 
� P values were calculated by
using McNemar’s test.
Az, area under the ROC curve; CI, confidence interval.
Diagnostic
values
PET/CT alone PET/CT plus 
Brain MRI
P values
Az value 0.106*
Value 0.830 0.896
95% CI 0.769, 0.890 0.850, 0.94
Sensitivity (%)
� 68 (60/88) 84 (74/88) 0.03
�
Specificity (%)
� 98 (346/354) 95 (337/354) 0.22
�
Accuracy (%)
� 92 (406/442) 93 (411/442) 0.80
�
Table 4. ROC analysis and sensitivity and specificity in detec-
tion of all extrathoracic metastases
*P values were calculated by using Z test; 
� Data in parentheses are the
values used to calculate the percentage; 
� P values were calculated by
using McNemar’s test.
Az, area under the ROC curve; CI, confidence interval.PET/CT Plus Brain MRI for Metastasis Detection in Lung Adenocarcinoma 1135
marized in Tables 3, 4. By adding contrast enhanced MRI
to PET/CT, brain metastases were detected in additional 32
(7.2% of 442 patients; 44 in MRI plus PET/CT vs. 12 in
PET/CT only) patients, in whom the treatment modality
should have been changed. For the assessment of brain metas-
tases on a per-patient basis, brain MRI showed a significantly
greater area under the ROC curve (Az) than PET/CT (0.985
vs. 0.619; P<0.001) did. In terms of sensitivity for the detec-
tion of brain metastasis, a significant difference was found
between brain MRI and PET/CT (88% vs. 24%; P<0.001).
For the neurologically asymptomatic cases, the sensitivity of
brain MRI was significantly higher than that of PET/CT (86%
vs. 19%; P<0.001). Sizes (measured on enhanced T1-weight-
ed images of brain MRI) of PET-detected brain metastases
Numbers are per patient. 
*Maximal size of the brain metastatic lesions.
False positive findings Methods False negative findings
PET/CT 1 Uneven physiologic uptake  (n=1) 38 <5 mm* (n=22)
5-10 mm* (n=7)
>10 mm* (n=3)
Not identified in retrospect and unexpected metastasis 
during 6-month follow-up period (n=6)
Brain MRI 7 Flow-related enhancement  (n=6) 6 Not identified in retrospect and unexpected metastasis
Hemorrhage (n=1) during 6-month follow-up period (n=6)
Table 5. Causes of false-positive and false-negative lesions as determined by brain MRI and PET/CT 
Fig. 1. A 42-yr-old woman with lung adenocarcinoma and brain metastases. Contrast-enhanced T1-weighted brain MR image (A)
clearly demonstrates the presence of cerebellar metastasis (arrow). PET/CT and PET images (B, C) show decreased FDG-uptake. 
A B C
Fig. 2. A 27-yr-old man with lung adenocarcinoma and multiple brain metastases. Contrast-enhanced T1-weighted brain MR image
(A) shows the presence of multiple small metastases less than 5 mm in diameter (arrows). However, axial images (B, C) of PET/CT
and PET images do not indicate the abnormal FDG-uptaking lesion. 
A B C1136 H.Y. Lee, K.S. Lee, B.-T. Kim, et al.
were significantly larger (mean, 27 mm; range, 10-47 mm)
than those of PET-missed lesions (mean, 6 mm; range, 1-28
mm) (P=0.002). 
ROC analysis determined that PET/CT plus brain MRI was
superior to PET/CT for the detection of overall extrathoracic
metastases, although statistical significance was not reached
(0.896 vs. 0.830; P=0.106). In terms of sensitivity for the
detection of overall extrathoracic metastases, a significant dif-
ference was found between PET/CT and PET/CT plus brain
MRI (68% vs. 84%; P=0.03). 
False-negative and false-positive
A listing of false-positive and false-negative cases for brain
metastases of lung adenocarcinoma patients identified by means
of the two methods is shown in Table 5. Representative cases
are shown in Figs. 1, 2. PET/CT could not depict 22 metastat-
ic foci of <5 mm in diameter. At brain MRI, all false nega-
tive lesions were noted during the follow-up period and were
not identified at the initial imaging study, retrospectively. 
DISCUSSION
Preoperative evaluation with diagnostic imaging for brain
metastases in NSCLC patients remains controversial issue
(14, 15). One meta-analysis in patients with no neurologi-
cal abnormality on a clinical examination demonstrated the
negative predictive value in this setting as 95% (16). In con-
trast, a recent report by Jena et al. (17) stated that an asymp-
tomatic brain metastasis occurs in 17% (29 of 175; 158 [90%]
of 175 patients had stage IV cancer) of lung cancer patients
with almost equal number of symptomatic (33 of 62 [53%]
patients with a brain metastasis) and asymptomatic (29 of
62 [47%]patients) metastases. In the current study (relatively
even distribution of patient cancer stages, 124 [28%] of 442
patients had stage IV cancers), 50 (11%) of the 442 lung ade-
nocarcinoma patients had a brain metastasis, and of these 50
patients, 30 (60%) patients had one organ (brain) metastasis
only and 35 (70%) patients had a single lesion metastasis.
Only seven (14%) patients complained of any neurological
symptoms and signs. 
The brain is often the only site of distant metastatic disease
and approximately one-third of patients will have limited,
potentially resectable lung tumors without distant metastases
other than a brain metastasis (18). In the most recent ACCP
guidelines (19), the use of routine staging of the central ner-
vous system (CNS) system is considered in level 2C for stage
III malignancies. However, 53% of the patients with single
metastasis to brain in our study had stage I or II lung ade-
nocarcinoma. The prognosis in patients with a brain metas-
tasis who are untreated is extremely poor (about one month
survival after diagnosis), whereas patients with NSCLC who
were treated with local radiation therapy survived for about
eight months (20, 21). Therefore, early and accurate diagno-
sis of a brain metastasis is crucial to improve quality of life
and the poor survival rates of lung cancer patients.
For the assessment of brain metastases on a per-patient
basis, our results showed that the Az value of brain MRI is
significantly larger than that of PET/CT. In addition, the sen-
sitivity of brain MRI is significantly higher than that of PET/
CT. This result is in accord with findings of recent studies
by Ohno et al. (21) and Yi et al. (22), which has found higher
sensitivity of MRI than FDG PET or PET/CT for the detec-
tion of brain metastasis is determined. The disparity in sen-
sitivity between brain MRI and PET/CT can be caused by
the extremely high level of physiological tissue accumula-
tion of FDG in the cerebral cortex as depicted at PET, which
hinders the identification of metastatic disease in the brain,
and by the insufficient spatial resolution of PET for the detec-
tion of a metastasis less than 5 mm.
On a per-patient basis, all false negative lesions on brain
MRI were also assessed as false negative on PET, and there
was no lesion which was detected on PET. The lesions were
regarded as metastatic (growth from a microscopic metastat-
ic focus) because all lesions were detected by follow-up stud-
ies in six months or more. Considering these results, torso
PET plus brain MRI would provide enough information
about brain metastasis and appears to be efficient for M stag-
ing in NSCLC patients as much as brain and body PET plus
brain MRI.
In our study, by adding contrast enhanced MRI to PET/
CT, brain metastases were detected in additional 32 (7% of
442) patients, in whom treatment modality should have been
changed. Therefore, imaging surveillance of the brain for
metastases is worthwhile in the context that neurologically
asymptomatic metastases can be detected early to provide
appropriate therapy, especially in patients with lung adeno-
carcinoma where asymptomatic metastases are more frequent
than in other NSCLC (23-25).
Our study has several limitations. First and most impor-
tantly, because we did not administer IV contrast medium
for CT image acquisition at PET/CT, CT component images
might have played a role as transmission data only image
coregistration and have provided little morphologic infor-
mation for metastasis detection. This might have contribut-
ed to lowering sensitivity for detecting brain or other organ
(e.g., hepatic, renal, and splenic) metastasis at PET/CT. There-
fore, our comparison is more of PET alone versus PET plus
MRI brain, rather than PET/CT alone versus PET/CT plus
MRI brain. Obtaining contrast-enhanced CT component
images at PET/CT would provide more precise anatomic
information for abnormal lesions by enhancing attenuation
differences between lesions and surrounding normal struc-
tures especially in such cases as brain, hepatic, renal or splenic
metastasis. However, controversies on having enhanced CT
component of PET/CT are still ongoing, because concerns
over contrast medium injection in terms of technical, eco-PET/CT Plus Brain MRI for Metastasis Detection in Lung Adenocarcinoma 1137
nomic, work-flow, and radiation-safety issues has been raised.
Second, we were unable to make a pathologic diagnosis of
an extrathoracic metastasis at a given site in every patient.
This may suggest that the sensitivity and specificity values
in the current study might be biased. Third, brain MRI is
not routinely included as a standard initial staging workup
in clinical practice at other institutions and we did not cal-
culate the cost-effectiveness of the addition of brain MRI to
PET/CT. A further study needs to be performed as to the cost-
effectiveness on our protocol for the addition of brain MRI
to PET or PET/CT.
In conclusion, with the addition of dedicated brain MRI to
PET/CT and thus with enhanced brain metastasis detection,
a significant increase in diagnostic sensitivity can be achieved
for detecting extrathoracic metastases in patients with lung
adenocarcinoma. Thus, adding dedicated brain MRI to PET/
CT appears to be efficient for M staging in patients who have
a histopathologically confirmed lung adenocarcinoma.
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